Incidence of serious adverse events was similar between treatment groups ( QVA149 , 13 of 258 [ 50 % ] ; SFC 14 of 264 [ 53 % ] ) ; COPD worsening was the most frequent serious adverse event ( one of 13 [ 04 % ] and three of 14 [ 11 % ] , respectively ) .